Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio

David Eugeny Godler, Flora Tassone, Danuta Zuzanna Loesch, Annette Kimball Taylor, Freya Gehling, Randi J Hagerman, Trent Burgess, Devika Ganesamoorthy, Debbie Hennerich, Lavinia Gordon, Andrew Evans, K. H. Choo, Howard Robert Slater

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The fragile X syndrome (FXS) is caused by silencing of the fragile X mental retardation gene (FMR1) and the absence of its product, fragile X mental retardation protein (FMRP), resulting from CpG island methylation associated with large CGG repeat expansions (more than 200) termed full mutation (FM). We have identified a number of novel epigenetic markers for FXS using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), naming the most informative fragile X-related epigenetic element 1 (FREE1) and 2 (FREE2). Methylation of both regions was correlated with that of the FMR1 CpG island detected using Southern blot (FREE1 R = 0.97; P < 0.00001, n = 23 and FREE2 R = 0.93; P < 0.00001, n = 23) and nega- tively correlated with lymphocyte expression of FMRP (FREE1 R 520.62; P = 0.01, n = 15 and FREE2 R 520.55; P = 0.03, n = 15) in blood of partially methylated 'high functioning' FM males. In blood of FM carrier females, methylation of both markers was inversely correlated with the FMR1 activation ratio (FREE1 R 520.93; P < 0.0001, n = 12 and FREE2 R 520.95; P < 0.0001, n = 9). In a sample set of 49 controls, 18 grey zone (GZ 40-54 repeats), 22 premutation (PM 55-170 repeats) and 22 (affected) FXS subjects, the FREE1 methylation pattern was consistent between blood and chorionic villi as a marker of methylated FM alleles and could be used to differentiate FXS males and females from controls, as well as from carriers of GZ/PM alleles, but not between GZ and PM alleles and controls. Considering its high-throughput and speci- ficity for pathogenic FM alleles, low cost and minimal DNA requirements, FREE MALDI-TOF MS offers a unique tool in FXS diagnostics and newborn population screening.

Original languageEnglish (US)
Article numberddq037
Pages (from-to)1618-1632
Number of pages15
JournalHuman Molecular Genetics
Volume19
Issue number8
DOIs
StatePublished - Jan 29 2010

Fingerprint

Fragile X Mental Retardation Protein
Fragile X Syndrome
Epigenomics
Methylation
Alleles
Mutation
CpG Islands
Mass Spectrometry
Lasers
Chorionic Villi
Southern Blotting
Intellectual Disability
Lymphocytes
Costs and Cost Analysis
DNA

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. / Godler, David Eugeny; Tassone, Flora; Loesch, Danuta Zuzanna; Taylor, Annette Kimball; Gehling, Freya; Hagerman, Randi J; Burgess, Trent; Ganesamoorthy, Devika; Hennerich, Debbie; Gordon, Lavinia; Evans, Andrew; Choo, K. H.; Slater, Howard Robert.

In: Human Molecular Genetics, Vol. 19, No. 8, ddq037, 29.01.2010, p. 1618-1632.

Research output: Contribution to journalArticle

Godler, DE, Tassone, F, Loesch, DZ, Taylor, AK, Gehling, F, Hagerman, RJ, Burgess, T, Ganesamoorthy, D, Hennerich, D, Gordon, L, Evans, A, Choo, KH & Slater, HR 2010, 'Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio', Human Molecular Genetics, vol. 19, no. 8, ddq037, pp. 1618-1632. https://doi.org/10.1093/hmg/ddq037
Godler, David Eugeny ; Tassone, Flora ; Loesch, Danuta Zuzanna ; Taylor, Annette Kimball ; Gehling, Freya ; Hagerman, Randi J ; Burgess, Trent ; Ganesamoorthy, Devika ; Hennerich, Debbie ; Gordon, Lavinia ; Evans, Andrew ; Choo, K. H. ; Slater, Howard Robert. / Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. In: Human Molecular Genetics. 2010 ; Vol. 19, No. 8. pp. 1618-1632.
@article{2cdde39920cc462ba230fb1bd3760d5d,
title = "Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio",
abstract = "The fragile X syndrome (FXS) is caused by silencing of the fragile X mental retardation gene (FMR1) and the absence of its product, fragile X mental retardation protein (FMRP), resulting from CpG island methylation associated with large CGG repeat expansions (more than 200) termed full mutation (FM). We have identified a number of novel epigenetic markers for FXS using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), naming the most informative fragile X-related epigenetic element 1 (FREE1) and 2 (FREE2). Methylation of both regions was correlated with that of the FMR1 CpG island detected using Southern blot (FREE1 R = 0.97; P < 0.00001, n = 23 and FREE2 R = 0.93; P < 0.00001, n = 23) and nega- tively correlated with lymphocyte expression of FMRP (FREE1 R 520.62; P = 0.01, n = 15 and FREE2 R 520.55; P = 0.03, n = 15) in blood of partially methylated 'high functioning' FM males. In blood of FM carrier females, methylation of both markers was inversely correlated with the FMR1 activation ratio (FREE1 R 520.93; P < 0.0001, n = 12 and FREE2 R 520.95; P < 0.0001, n = 9). In a sample set of 49 controls, 18 grey zone (GZ 40-54 repeats), 22 premutation (PM 55-170 repeats) and 22 (affected) FXS subjects, the FREE1 methylation pattern was consistent between blood and chorionic villi as a marker of methylated FM alleles and could be used to differentiate FXS males and females from controls, as well as from carriers of GZ/PM alleles, but not between GZ and PM alleles and controls. Considering its high-throughput and speci- ficity for pathogenic FM alleles, low cost and minimal DNA requirements, FREE MALDI-TOF MS offers a unique tool in FXS diagnostics and newborn population screening.",
author = "Godler, {David Eugeny} and Flora Tassone and Loesch, {Danuta Zuzanna} and Taylor, {Annette Kimball} and Freya Gehling and Hagerman, {Randi J} and Trent Burgess and Devika Ganesamoorthy and Debbie Hennerich and Lavinia Gordon and Andrew Evans and Choo, {K. H.} and Slater, {Howard Robert}",
year = "2010",
month = "1",
day = "29",
doi = "10.1093/hmg/ddq037",
language = "English (US)",
volume = "19",
pages = "1618--1632",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio

AU - Godler, David Eugeny

AU - Tassone, Flora

AU - Loesch, Danuta Zuzanna

AU - Taylor, Annette Kimball

AU - Gehling, Freya

AU - Hagerman, Randi J

AU - Burgess, Trent

AU - Ganesamoorthy, Devika

AU - Hennerich, Debbie

AU - Gordon, Lavinia

AU - Evans, Andrew

AU - Choo, K. H.

AU - Slater, Howard Robert

PY - 2010/1/29

Y1 - 2010/1/29

N2 - The fragile X syndrome (FXS) is caused by silencing of the fragile X mental retardation gene (FMR1) and the absence of its product, fragile X mental retardation protein (FMRP), resulting from CpG island methylation associated with large CGG repeat expansions (more than 200) termed full mutation (FM). We have identified a number of novel epigenetic markers for FXS using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), naming the most informative fragile X-related epigenetic element 1 (FREE1) and 2 (FREE2). Methylation of both regions was correlated with that of the FMR1 CpG island detected using Southern blot (FREE1 R = 0.97; P < 0.00001, n = 23 and FREE2 R = 0.93; P < 0.00001, n = 23) and nega- tively correlated with lymphocyte expression of FMRP (FREE1 R 520.62; P = 0.01, n = 15 and FREE2 R 520.55; P = 0.03, n = 15) in blood of partially methylated 'high functioning' FM males. In blood of FM carrier females, methylation of both markers was inversely correlated with the FMR1 activation ratio (FREE1 R 520.93; P < 0.0001, n = 12 and FREE2 R 520.95; P < 0.0001, n = 9). In a sample set of 49 controls, 18 grey zone (GZ 40-54 repeats), 22 premutation (PM 55-170 repeats) and 22 (affected) FXS subjects, the FREE1 methylation pattern was consistent between blood and chorionic villi as a marker of methylated FM alleles and could be used to differentiate FXS males and females from controls, as well as from carriers of GZ/PM alleles, but not between GZ and PM alleles and controls. Considering its high-throughput and speci- ficity for pathogenic FM alleles, low cost and minimal DNA requirements, FREE MALDI-TOF MS offers a unique tool in FXS diagnostics and newborn population screening.

AB - The fragile X syndrome (FXS) is caused by silencing of the fragile X mental retardation gene (FMR1) and the absence of its product, fragile X mental retardation protein (FMRP), resulting from CpG island methylation associated with large CGG repeat expansions (more than 200) termed full mutation (FM). We have identified a number of novel epigenetic markers for FXS using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), naming the most informative fragile X-related epigenetic element 1 (FREE1) and 2 (FREE2). Methylation of both regions was correlated with that of the FMR1 CpG island detected using Southern blot (FREE1 R = 0.97; P < 0.00001, n = 23 and FREE2 R = 0.93; P < 0.00001, n = 23) and nega- tively correlated with lymphocyte expression of FMRP (FREE1 R 520.62; P = 0.01, n = 15 and FREE2 R 520.55; P = 0.03, n = 15) in blood of partially methylated 'high functioning' FM males. In blood of FM carrier females, methylation of both markers was inversely correlated with the FMR1 activation ratio (FREE1 R 520.93; P < 0.0001, n = 12 and FREE2 R 520.95; P < 0.0001, n = 9). In a sample set of 49 controls, 18 grey zone (GZ 40-54 repeats), 22 premutation (PM 55-170 repeats) and 22 (affected) FXS subjects, the FREE1 methylation pattern was consistent between blood and chorionic villi as a marker of methylated FM alleles and could be used to differentiate FXS males and females from controls, as well as from carriers of GZ/PM alleles, but not between GZ and PM alleles and controls. Considering its high-throughput and speci- ficity for pathogenic FM alleles, low cost and minimal DNA requirements, FREE MALDI-TOF MS offers a unique tool in FXS diagnostics and newborn population screening.

UR - http://www.scopus.com/inward/record.url?scp=77952304162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952304162&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddq037

DO - 10.1093/hmg/ddq037

M3 - Article

C2 - 20118148

AN - SCOPUS:77952304162

VL - 19

SP - 1618

EP - 1632

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 8

M1 - ddq037

ER -